Russia plans to accelerate antibiotic APIs production

Russia plans to accelerate the production of active pharmaceutical ingredients (APIs) for antibiotics, as well as to pay more attention to the development of drugs against chronic infections, as part of a new State Concept for the Development of Pharmaceutical industry in Russia that is designed until 2030, reports The Pharma Letter’s local correspondent.

Among the participants of the project are expected to be some largest Russian pharmaceutical companies: R-Pharm, Biocad, Active Component, ChemRar and others. As part of the project, it is proposed to attract universities and research universities for its implementation, while the list of them will included the Lomonosov Moscow State University. Lomonosov, Sirius University, the Center of Gamaleya and the Center of Chumakov, of the Russian Academy of Sciences, etc.

A part of the state plan is providing up to 200 billion roubles ($3.5 billion) for these projects, most local experts consider this is insufficient, believing that the real figure required for implementation of these plans is estimated at 500 billion roubles.